Crucially, because there are already multiple treatments for AS that aim to upregulate UBE3A, these strategies could be repurposed or adapted to address UBE3A deficits in other neurocognitive disorders such as Alzheimer’s disease and related neurodegenerative conditions. Here, UBE3A is linked to Alzheimer disease.